{"id":276275,"date":"2026-01-09T17:37:05","date_gmt":"2026-01-09T17:37:05","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/276275\/"},"modified":"2026-01-09T17:37:05","modified_gmt":"2026-01-09T17:37:05","slug":"schrodinger-to-offer-eli-lillys-ai-drug-discovery-platform-on-its-software","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/276275\/","title":{"rendered":"Schrodinger to offer Eli Lilly&#8217;s AI drug discovery platform on its software"},"content":{"rendered":"<p>Jan 9 (Reuters) &#8211; Schrodinger <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/SDGR.O\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(SDGR.O), opens new tab<\/a> said on Friday it is collaborating with Eli Lilly <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/LLY.N\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(LLY.N), opens new tab<\/a> to offer the pharmaceutical major&#8217;s AI-based platform, TuneLab, on its drug designing software.<\/p>\n<p>Integration of Lilly&#8217;s TuneLab into Schrodinger&#8217;s LiveDesign will give biotech companies direct access to the artificial intelligence platform to help speed up drug development, the biotech software maker said.<\/p>\n<p data-testid=\"promo-box\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf article-body-module__promo-box__hVl8h\"> Sign up  <a data-testid=\"Link\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/schrodinger-offer-eli-lillys-ai-drug-discovery-platform-its-software-2026-01-09\/undefined?location=article-paragraph&amp;redirectUrl=%2Fbusiness%2Fhealthcare-pharmaceuticals%2Fschrodinger-offer-eli-lillys-ai-drug-discovery-platform-its-software-2026-01-09%2F\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC\" rel=\"nofollow noopener\" target=\"_blank\">here.<\/a><\/p>\n<p>Schrodinger&#8217;s cloud-based platform, LiveDesign, helps chemists design compounds and predict the properties such as absorption and distribution of the experimental drug, helping them understand how a drug will behave in the body.<\/p>\n<p>Drug developers are <a data-testid=\"Link\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/ai-driven-drug-discovery-picks-up-fda-pushes-reduce-animal-testing-2025-09-02\/\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC\" rel=\"nofollow noopener\" target=\"_blank\">increasing<\/a> adoption of AI for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in the near future.<\/p>\n<p>Current LiveDesign clients will be able to use TuneLab in the first quarter of this year, while the AI software will be available to new users by the second quarter, Schrodinger&#8217;s Chief Strategy Officer Karen Akinsanya said.<\/p>\n<p>Lilly <a data-testid=\"Link\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/lilly-launches-ai-powered-platform-accelerate-drug-discovery-2025-09-09\/\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC\" rel=\"nofollow noopener\" target=\"_blank\">launched<\/a> TuneLab, an AI and machine learning platform, last year to provide biotech companies access to drug discovery models trained on years of its research data. The drugmaker has already announced partnerships with several biotech companies to use its platform to develop drugs.<\/p>\n<p>&#8220;More biotechs using the models means more diverse training data&#8230; Ultimately, this is about moving molecules through discovery faster for the patients who are waiting,&#8221; Aliza Apple, global head of Lilly TuneLab, said.<\/p>\n<p data-testid=\"SignOff\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__extra_small__8Buss body-module__full_width__kCIGb body-module__extra_small_body__Bfz20 sign-off-module__text__LQAMP\">Reporting by Sneha S K in Bengaluru; Editing by Leroy Leo<\/p>\n<p data-testid=\"Body\" dir=\"ltr\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf article-body-module__element__5eCce article-body-module__trust-badge__5mS3f\">Our Standards: <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.thomsonreuters.com\/en\/about-us\/trust-principles.html\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__medium__2Rl30 text-module__small__sph8i link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">The Thomson Reuters Trust Principles., opens new tab<\/a><\/p>\n<p><a href=\"https:\/\/www.reutersagency.com\/en\/licensereuterscontent\/?utm_medium=rcom-article-media&amp;utm_campaign=rcom-rcp-lead\" target=\"_blank\" dir=\"ltr\" class=\"button-module__link__A3sD0 button-module__secondary__70gBu button-module__round__QDFgq button-module__w_auto__Sem-F\" data-testid=\"LicenceContentButton\" rel=\"nofollow noopener\">Purchase Licensing Rights<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Jan 9 (Reuters) &#8211; Schrodinger (SDGR.O), opens new tab said on Friday it is collaborating with Eli Lilly&hellip;\n","protected":false},"author":2,"featured_media":276276,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[82519,82793,82499,36586,82500,82795,82559,87652,87219,82529,18,45748,87209,135,475,474,87211,19,17,82797,84435,721,93734,82565,82524,87647,2765,88228,88229,82510,83002,82558,82512,84106,84107,82801,753,82999,30150,107],"class_list":{"0":"post-276275","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-amers","9":"tag-arti","10":"tag-bact","11":"tag-biz","12":"tag-cmpny","13":"tag-cprod","14":"tag-destlita","15":"tag-destohlt","16":"tag-destoushem","17":"tag-destoustcm","18":"tag-eire","19":"tag-gen","20":"tag-hea","21":"tag-health","22":"tag-health-care","23":"tag-healthcare","24":"tag-heca","25":"tag-ie","26":"tag-ireland","27":"tag-itec","28":"tag-itse","29":"tag-legal","30":"tag-mlaisv","31":"tag-mtpix","32":"tag-namer","33":"tag-nrlpaohlt","34":"tag-phar","35":"tag-phar1","36":"tag-phmr","37":"tag-publ","38":"tag-pxp","39":"tag-reuters-legal","40":"tag-sci","41":"tag-sofw","42":"tag-sofw1","43":"tag-swit","44":"tag-tech","45":"tag-teeq","46":"tag-tmt","47":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115866359755836205","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/276275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=276275"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/276275\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/276276"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=276275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=276275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=276275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}